IDYA
Price
$24.30
Change
-$0.62 (-2.49%)
Updated
Aug 29, 04:25 PM (EDT)
Capitalization
2.18B
74 days until earnings call
SNDX
Price
$16.03
Change
-$0.29 (-1.78%)
Updated
Aug 29, 04:19 PM (EDT)
Capitalization
1.41B
74 days until earnings call
Interact to see
Advertisement

IDYA vs SNDX

Header iconIDYA vs SNDX Comparison
Open Charts IDYA vs SNDXBanner chart's image
IDEAYA Biosciences
Price$24.30
Change-$0.62 (-2.49%)
Volume$1.08K
Capitalization2.18B
Syndax Pharmaceuticals
Price$16.03
Change-$0.29 (-1.78%)
Volume$2K
Capitalization1.41B
IDYA vs SNDX Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. SNDX commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a StrongBuy and SNDX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (IDYA: $24.93 vs. SNDX: $16.32)
Brand notoriety: IDYA and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 51% vs. SNDX: 93%
Market capitalization -- IDYA: $2.18B vs. SNDX: $1.41B
IDYA [@Biotechnology] is valued at $2.18B. SNDX’s [@Biotechnology] market capitalization is $1.41B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileSNDX’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • SNDX’s FA Score: 0 green, 5 red.
According to our system of comparison, SNDX is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 5 TA indicator(s) are bullish while SNDX’s TA Score has 5 bullish TA indicator(s).

  • IDYA’s TA Score: 5 bullish, 3 bearish.
  • SNDX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than SNDX.

Price Growth

IDYA (@Biotechnology) experienced а +1.22% price change this week, while SNDX (@Biotechnology) price change was +3.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.74%. For the same industry, the average monthly price growth was +15.52%, and the average quarterly price growth was +29.97%.

Reported Earning Dates

IDYA is expected to report earnings on Nov 11, 2025.

SNDX is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (-0.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($2.19B) has a higher market cap than SNDX($1.41B). SNDX YTD gains are higher at: 23.449 vs. IDYA (-2.996). SNDX has higher annual earnings (EBITDA): -314.25M vs. IDYA (-380.2M). IDYA has more cash in the bank: 670M vs. SNDX (469M). SNDX has less debt than IDYA: SNDX (1.68M) vs IDYA (26.6M). SNDX has higher revenues than IDYA: SNDX (77.9M) vs IDYA (7M).
IDYASNDXIDYA / SNDX
Capitalization2.19B1.41B155%
EBITDA-380.2M-314.25M121%
Gain YTD-2.99623.449-13%
P/E RatioN/AN/A-
Revenue7M77.9M9%
Total Cash670M469M143%
Total Debt26.6M1.68M1,588%
FUNDAMENTALS RATINGS
IDYA vs SNDX: Fundamental Ratings
IDYA
SNDX
OUTLOOK RATING
1..100
1130
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
84
Overvalued
PROFIT vs RISK RATING
1..100
7090
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5237
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (61) in the null industry is in the same range as SNDX (84) in the Biotechnology industry. This means that IDYA’s stock grew similarly to SNDX’s over the last 12 months.

IDYA's Profit vs Risk Rating (70) in the null industry is in the same range as SNDX (90) in the Biotechnology industry. This means that IDYA’s stock grew similarly to SNDX’s over the last 12 months.

IDYA's SMR Rating (100) in the null industry is in the same range as SNDX (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's Price Growth Rating (37) in the Biotechnology industry is in the same range as IDYA (52) in the null industry. This means that SNDX’s stock grew similarly to IDYA’s over the last 12 months.

SNDX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as IDYA (100) in the null industry. This means that SNDX’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYASNDX
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 15 days ago
77%
Bearish Trend 22 days ago
78%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ACAAX40.93N/A
N/A
Alger Capital Appreciation A
PLCIX65.90N/A
N/A
Voya Large-Cap Growth I
EDIRX11.30N/A
N/A
Eaton Vance Global Income Builder R
FSBDX22.10N/A
N/A
Fidelity Series Blue Chip Growth
TQVIX18.88N/A
N/A
T. Rowe Price Integrated US LCV Eq I

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with REPL. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
+0.37%
REPL - SNDX
51%
Loosely correlated
-2.71%
CGON - SNDX
49%
Loosely correlated
+0.89%
ETNB - SNDX
47%
Loosely correlated
+0.86%
IDYA - SNDX
47%
Loosely correlated
-0.28%
RNA - SNDX
47%
Loosely correlated
+1.59%
More